1 Ketamine is a dissociative anaesthetic that is formulated as Ketalar, which contains the preservative benzethonium chloride (BCl). We have studied the e ects of pure racemic ketamine, the preservative BCl and the Ketalar mixture on human neuronal nicotinic acetylcholine receptors (nAChRs) composed of the a7 subunit or a4 and b2 subunits expressed in Xenopus laevis oocytes. 2 Ketamine inhibited responses to 1 mM acetylcholine (ACh) in both the human a7 and a4b2 nAChRs, with IC 50 values of 20 and 50 mM respectively. Inhibition of the a7 nAChRs occurred within a clinically relevant concentration range, while inhibition of the a4b2 nAChR was observed only at higher concentrations. The Ketalar formulation inhibited nAChR function more e ectively than was expected given its ketamine concentration. The surprising increased inhibitory potency of Ketalar compared with pure ketamine appeared to be due to the activity of BCl, which inhibited both a7 (IC 50 value of 122 nM) and a4b2 (IC 50 value of 49 nM) nAChRs at concentrations present in the clinical formulation of Ketalar. 3 Ketamine is a noncompetitive inhibitor at both the a7 and a4b2 nAChR. In contrast, BCl causes a parallel shift in the ACh dose-response curve at the a7 nAChR suggesting competitive inhibition. Ketamine causes both voltage-dependent and use-dependent inhibition, only in the a4b2 nAChR. 4 Since a7 nAChRs are likely to be inhibited during clinical use of Ketalar, the actions of ketamine and BCl on this receptor subtype may play a role in the profound analgesia, amnesia, immobility and/or autonomic modulation produced by this anaesthetic. British Journal of Pharmacology (2001) 134, 871 ± 879 Keywords: Neuronal nicotinic acetylcholine receptors; benzethonium chloride; ketamine; anaesthetic mechanism Abbreviations: BCl, benzethonium chloride; nAChRs, neuronal nicotinic acetylcholine receptors
IntroductionKetamine is a dissociative anaesthetic, that is an e ective analgesic, amnestic and hypnotic, but causes hallucinations that limit its usefulness as a clinical anaesthetic agent. Due to its potency as an analgesic and its sympathomimetic properties, ketamine ®nds extensive use in the treatment of burn patients in intensive care settings. In the early 1980's Lodge described ketamine as a selective inhibitor of NMDA receptor activity and neuronal nicotinic receptors (nAChRs) on Renshaw cells of the cat spinal cord (Anis et al., 1983). Ketamine is also an antagonist of NMDA receptors in rat cortex (Harrison & Simmonds, 1985) and blocks these receptors at sub-clinical concentrations, by acting both as a use-dependent open channel blocker (Honey et al., 1985) and through allosteric inhibition (Orser et al., 1997). Ketamine inhibits the response to acetylcholine or nicotine in both muscle and neuronal type nAChRs (Sumikawa et al., 1983;Wachtel & Wegrzynowicz, 1992;Scheller et al., 1996;Durieux, 1995;Furuya et al., 1999;Flood & Krasowski, 2000;Friederich et al., 2000;Sasaki et al., 2000;Yamakura et al., 2000). In the case of nAChRs containing the a4 subunit, ...